Oncodesign Precision Medicine: Publication of the 2023 Financial Calendar
08 2월 2023 - 2:00AM
Business Wire
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ;
Mnémonique : ALOPM) (Paris:ALOPM), a biopharmaceutical
company specializing in precision medicine for the treatment of
resistant and metastatic cancers, today publishes its indicative
financial calendar for 2023.
Event
Date*
2022 Annual Results
April 4, 2023
Annual General Meeting
May 30, 2023
2023 First Half Results
September 19, 2023
*subject to modification. Publication after financial market
close.
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers.
OPM's innovative technologies are (i) OncoSNIPER for the
selection of therapeutic targets using artificial intelligence;
(ii) Nanocyclix® for the design and selection of macrocyclic small
molecule kinase inhibitors and (iii) Theranostics for the design
and selection of radiolabeled biological molecules for systemic
radiotherapy.
From these technologies, OPM has built a portfolio of
therapeutic products. Two drug candidates based on the Nanocyclix
technology have completed regulatory filing, one in partnership
with SERVIER (exercise of the exclusive worldwide license option)
to treat Parkinson's disease and ODS 101 with OPM for the treatment
of chronic immuno-inflammatory diseases. Finally, OPM is also
collaborating with Servier to discover new therapeutic targets for
the treatment of pancreatic adenocarcinoma based on its OncoSNIPER
technology. In addition, OPM is seeking a partner for Florepizol, a
radiotracer specific to the mutated EGFR target, which has
successfully completed Phase 1. Two projects are in early
partnership phase with TIUM BIO (pulmonary fibrosis) and SEngine in
oncology. Finally, OPM has a significant portfolio of early stage
projects with Nanocyclix® and Theranostics in oncology. With this
portfolio of molecules and diversified therapeutic targets, OPM's
mission is to discover effective therapies to treat resistant and
advanced cancers. Based in Dijon, at the heart of the university
and hospital cluster, OPM has 25 employees.
More information: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230207005991/en/
OPM Philippe Genne Chairman and CEO Phone: +33 (0)3 80 78
82 60 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Phone: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Phone: +33 (0)1 44
71 00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
